Zhang Zhong-Hua, Chen Yi, Zhao Hua-Jun, Xie Cheng-Ying, Ding Jian, Hou Yong-Tai
Division of Molecular Pharmacology, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, PR China.
Cancer Biol Ther. 2007 Apr;6(4):587-95. doi: 10.4161/cbt.6.4.3888.
Expression of the heparanase gene is associated with invasive, angiogenic and metastatic potential of diverse malignant tumors and cell lines. Here we used RNA interference strategies to evaluate the role of human heparanase in breast malignancy and to explore the therapeutic potential of its specific targeting. The siRNA targeting human heparanase almost completely inhibited the expression of heparanase in human breast carcinoma MDA-MB-435 cells, whereas the mismatched siRNA showed no effect. Cells transfected with heparanase siRNA expressed significantly less heparanase and profoundly reduced invasion and adhesion in vitro. In MDA-MB-435 cell xenograft model, tumors treated with siRNA were less vascularized and less metastatic than those treated with saline and the mismatched controls. The association of reduced levels of heparanase and altered tumorigenic properties in cells with anti-heparanase siRNA indicates that heparanase is important in cancer progress and has potential use as a target for anticancer drug development.
乙酰肝素酶基因的表达与多种恶性肿瘤和细胞系的侵袭、血管生成及转移潜能相关。在此,我们运用RNA干扰策略来评估人乙酰肝素酶在乳腺恶性肿瘤中的作用,并探索其特异性靶向的治疗潜力。靶向人乙酰肝素酶的小干扰RNA(siRNA)几乎完全抑制了人乳腺癌MDA-MB-435细胞中乙酰肝素酶的表达,而错配的siRNA则无此作用。用乙酰肝素酶siRNA转染的细胞表达的乙酰肝素酶显著减少,且体外侵袭和黏附能力大幅降低。在MDA-MB-435细胞异种移植模型中,与用生理盐水及错配对照处理的肿瘤相比,用siRNA处理的肿瘤血管化程度较低且转移较少。抗乙酰肝素酶siRNA处理的细胞中乙酰肝素酶水平降低与致瘤特性改变之间的关联表明,乙酰肝素酶在癌症进展中起重要作用,并且有潜力用作抗癌药物开发的靶点。